$854 Million is the total value of Logos Global Management LP's 40 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 69.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IDYA | Sell | IDEAYA BIOSCIENCES INC | $70,863,000 | +14.9% | 3,900,000 | -5.7% | 8.30% | +9.5% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $69,808,500 | -21.4% | 1,350,000 | +3.8% | 8.18% | -25.1% |
| CYTK | Sell | CYTOKINETICS INC | $68,730,000 | -16.6% | 1,500,000 | -11.8% | 8.05% | -20.5% |
| IMVT | New | IMMUNOVANT INC | $55,912,500 | – | 3,150,000 | +100.0% | 6.55% | – |
| ALLK | Sell | ALLAKOS INC | $44,513,728 | +22.5% | 5,286,666 | -10.9% | 5.22% | +16.7% |
| BCYC | Sell | BICYCLE THERAPEUTICS PLCsponsored ads | $42,476,000 | -8.7% | 1,435,000 | -28.2% | 4.98% | -13.0% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $35,487,000 | +96.6% | 900,000 | +80.0% | 4.16% | +87.3% |
| ISEE | IVERIC BIO INC | $32,115,000 | +19.3% | 1,500,000 | 0.0% | 3.76% | +13.7% | |
| KRTX | KARUNA THERAPEUTICS INC | $29,475,000 | -12.6% | 150,000 | 0.0% | 3.45% | -16.8% | |
| VRDN | VIRIDIAN THERAPEUTICS INC | $29,210,000 | +42.4% | 1,000,000 | 0.0% | 3.42% | +35.7% | |
| DSGN | DESIGN THERAPEUTICS INC | $28,702,360 | -38.6% | 2,797,501 | 0.0% | 3.36% | -41.5% | |
| IMCR | Buy | IMMUNOCORE HLDGS PLCads | $28,535,000 | +73.7% | 500,000 | +42.9% | 3.34% | +65.5% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $28,507,600 | -26.3% | 220,000 | -37.1% | 3.34% | -29.8% |
| ALXO | Sell | ALX ONCOLOGY HLDGS INC | $26,479,992 | -6.9% | 2,349,600 | -20.9% | 3.10% | -11.3% |
| DYN | Sell | DYNE THERAPEUTICS INC | $24,918,500 | -14.2% | 2,150,000 | -6.0% | 2.92% | -18.3% |
| AKRO | AKERO THERAPEUTICS INC | $21,920,000 | +60.9% | 400,000 | 0.0% | 2.57% | +53.4% | |
| Sell | VENTYX BIOSCIENCES INC | $21,543,555 | -55.8% | 657,016 | -53.0% | 2.52% | -57.9% | |
| ARQT | Sell | ARCUTIS BIOTHERAPEUTICS INC | $20,720,000 | -28.9% | 1,400,000 | -8.2% | 2.43% | -32.3% |
| Sell | DICE THERAPEUTICS INC | $20,592,000 | -6.4% | 660,000 | -39.2% | 2.41% | -10.9% | |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $17,415,000 | – | 60,000 | +100.0% | 2.04% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $14,677,500 | – | 750,000 | +100.0% | 1.72% | – |
| FULC | Buy | FULCRUM THERAPEUTICS INC | $14,560,000 | -7.7% | 2,000,000 | +2.6% | 1.71% | -12.0% |
| New | ASTRIA THERAPEUTICS INC | $12,879,254 | – | 864,960 | +100.0% | 1.51% | – | |
| COGT | New | COGENT BIOSCIENCES INC | $12,716,000 | – | 1,100,000 | +100.0% | 1.49% | – |
| GERN | Buy | GERON CORP | $9,680,000 | +106.8% | 4,000,000 | +100.0% | 1.13% | +97.2% |
| OLMA | OLEMA PHARMACEUTICALS INC | $9,172,494 | -11.2% | 3,743,875 | 0.0% | 1.08% | -15.4% | |
| FGEN | New | FIBROGEN INC | $8,410,500 | – | 525,000 | +100.0% | 0.98% | – |
| CERE | New | CEREVEL THERAPEUTICS HLDNG I | $8,200,400 | – | 260,000 | +100.0% | 0.96% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $7,837,500 | – | 1,250,000 | +100.0% | 0.92% | – |
| ANAB | New | ANAPTYSBIO INC | $7,747,500 | – | 250,000 | +100.0% | 0.91% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $6,838,200 | – | 180,000 | +100.0% | 0.80% | – |
| VERA | New | VERA THERAPEUTICS INCcl a | $5,514,750 | – | 285,000 | +100.0% | 0.65% | – |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $5,500,000 | – | 50,000 | +100.0% | 0.64% | – |
| RAPT | New | RAPT THERAPEUTICS INC | $3,960,000 | – | 200,000 | +100.0% | 0.46% | – |
| MOR | New | MORPHOSYS AGsponsored ads | $3,222,000 | – | 900,000 | +100.0% | 0.38% | – |
| Sell | VIGIL NEUROSCIENCE INC | $2,354,875 | +25.9% | 188,390 | -8.4% | 0.28% | +20.0% | |
| SPRB | SPRUCE BIOSCIENCES INC | $1,097,400 | -19.9% | 1,000,000 | 0.0% | 0.13% | -23.2% | |
| Sell | TYRA BIOSCIENCES INC | $842,506 | -24.7% | 110,856 | -12.9% | 0.10% | -28.3% | |
| Sell | LIANBIOsponsored ads | $459,200 | -25.5% | 280,000 | -9.1% | 0.05% | -28.9% | |
| NUVBWS | NUVATION BIO INC*w exp 07/07/202 | $9,633 | -25.9% | 66,666 | 0.0% | 0.00% | -50.0% | |
| Exit | PYXIS ONCOLOGY INC | $0 | – | -220,434 | -100.0% | -0.05% | – | |
| TALS | Exit | TALARIS THERAPEUTICS INC | $0 | – | -197,913 | -100.0% | -0.06% | – |
| TIL | Exit | INSTIL BIO INC | $0 | – | -331,872 | -100.0% | -0.20% | – |
| CNTA | Exit | CENTESSA PHARMACEUTICALS PLCsponsored ads | $0 | – | -399,801 | -100.0% | -0.20% | – |
| TCDA | Exit | TRICIDA INCput | $0 | – | -240,200 | -100.0% | -0.31% | – |
| IPSC | Exit | CENTURY THERAPEUTICS INC | $0 | – | -460,075 | -100.0% | -0.56% | – |
| CMPS | Exit | COMPASS PATHWAYS PLCsponsored ads | $0 | – | -510,000 | -100.0% | -0.67% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -950,000 | -100.0% | -1.01% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -800,000 | -100.0% | -1.04% | – |
| ALT | Exit | ALTIMMUNE INC | $0 | – | -750,000 | -100.0% | -1.18% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -950,000 | -100.0% | -1.22% | – |
| NGM | Exit | NGM BIOPHARMACEUTICALS INC | $0 | – | -850,000 | -100.0% | -1.37% | – |
| ASND | Exit | ASCENDIS PHARMA A/Ssponsored adr | $0 | – | -250,000 | -100.0% | -3.17% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.